Printer Friendly

AMERICAN ACADEMY OF PEDIATRICS RECOMMENDS USE OF ACELLULAR DTP VACCINE BY PEDIATRICIANS NATIONWIDE

 AMERICAN ACADEMY OF PEDIATRICS RECOMMENDS
 USE OF ACELLULAR DTP VACCINE BY PEDIATRICIANS NATIONWIDE
 WAYNE, N.J., April 30 /PRNewswire/ -- The American Academy of Pediatrics (AAP) Committee on Infectious Diseases has issued a recommendation that pediatricians nationwide can use the new acellular pertussis DTP vaccine for the fourth and fifth doses of the five-dose DTP immunization series. The FDA recently licensed the acellular DTP vaccine, ACEL-IMUNE(R) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).
 The publication of the AAP recommendations coincidentally follows the recent publication of an article in the Journal of the American Medical Association (JAMA), titled "Pertussis Hospitalizations and Mortality in the United States, 1985-1988." The article highlights a study which concludes that the number of pertussis (whooping couch) cases in the U.S. are substantially underreported, indicating that pertussis disease has a considerably higher impact in this country than once believed. This report is especially critical to pediatricians who must help parents make informed decisions about immunizing their children.
 The AAP Committee on Infectious Diseases reviews data and recommends use of vaccines and other drugs in policy statements and in its publication "Report of the Committee on Infectious Diseases." Recommendations by the AAP are highly regarded by pediatricians nationwide.
 The AAP policy statement on an acellular pertussis vaccine is significant to pediatricians and parents because it follows an AAP policy statement issued


in May 1991, supporting the introduction of acellular pertussis vaccines in the U.S. The policy was developed based on studies demonstrating that the acellular pertussis vaccine is effective and reduces side effects.
 ACEL-IMUNE, which is available from Lederle-Praxis Biologicals, a business unit of America Cyanamid, protects children against diphtheria, tetanus and pertussis (whooping cough) and is licensed for use in children at approximately 18 months ago of age and again between four and six years of age. These represent the fourth and fifth doses of the five-dose DTP immunization series.
 "The recommendation is welcomed by pediatricians because it gives them official guidance from their organization on how to use the latest weapon in the fight against pertussis," said Ronald Saldarini, Ph.D., president and chief executive officer, Lederle-Praxis Biologicals.
 ACEL-IMUNE represents an advance over the whole-cell DTP vaccine currently manufactured by Lederle Laboratories because it contains an acellular pertussis component. This leads to a reduction in local reactions such as pain, tenderness, redness, induration and injection site temperature compared with the whole-cell DTP vaccine manufactured by Lederle. ACEL-IMUNE also causes less fever, drowsiness, fretfulness than the current Lederle whole-cell DTP vaccine.
 Like all vaccines, the administration of ACEL-IMUNE may cause some minor, temporary side effects at the injection site, but clinical trials demonstrate the degree of these reactions were less than with the whole- cell DTP vaccine manufactured by Lederle.
 Lederle-Praxis Biologicals, an American Cyanamid business unit, is a leading developer, marketer and distributor of several important vaccine products. In addition to ACEL-IMUNE, other vaccines available through Lederle-Praxis Biologicals include those to prevent polio, Haemophilus b meningitis, pneumococcal pneumonia, influenza, and the current whole- cell DTP vaccine.
 ACEL-IMUNE is manufactured by Lederle Laboratories, a division of American Cyanamid Company, and distributed by Lederle-Praxis Biologicals, a Cyanamid business unit. The acellular pertussis vaccine component is manufactured by Takeda Chemical Industries of Japan.
 -0- 4/30/92
 /NOTE TO EDITORS: A copy of the ACEL-IMUNE package insert is available from Lederle-Praxis Biologicals./
 /CONTACT: Craig Engesser of Lederle-Praxis Biologicals, 201-831-3253/ CO: Lederle-Praxis Biologicals ST: New Jersey IN: MTC SU: PS-SM -- NY005 -- 4823 04/30/92 10:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:582
Previous Article:RESEARCH FRONTIERS' JAPANESE LICENSEE DEMONSTRATES WALL OF 'SMART' WINDOWS
Next Article:NOVA CORPORATION OF ALBERTA UNDERWRITERS EXERCISE OPTION


Related Articles
CONNAUGHT LABORATORIES, INC. RECEIVES ACELLULAR DTP VACCINE LICENSE
CONNAUGHT LABORATORIES RECEIVES CDC CONTRACT TO SUPPLY ACELLULAR DTP VACCINE FOR PUBLIC SECTOR
New DTP vaccine licensed.
GERMANY IS FIRST WORLDWIDE LAUNCH FOR SMITHKLINE BEECHAM'S NEW ACELLULAR PERTUSSIS VACCINE, INFANRIX
ACELLULAR PERTUSSIS VACCINE APPEARS TO BE SAFE & EFFECTIVE FOR INFANTS; GERMAN STUDY SUPPORTS VACCINE LIKE ONE USED IN U.S. FOR BOOSTER SHOTS
FIRST ACELLULAR PERTUSSIS VACCINE APPROVED FOR INFANTS
Abbott Announces CERTIVA(TM) Launch.
$500 Million Products Liability Lawsuit Filed Against American Home Products Corporation for Permanent Brain Damage Allegedly Caused by the Use of...
Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia(R) to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters